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E7080, a multi-targeted tyrosine kinase inhibitor
suppresses tumor cell migration and invasion
Hilary Glen1, Susan Mason1, Hitesh Patel2, Kenneth Macleod2 and Valerie G Brunton2*
Abstract
Background: E7080 is an orally active multi-targeted kinase inhibitor whose targets include vascular endothelial
growth factor receptors (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor
receptors (PDGFR). It has been shown to inhibit tumor angiogenesis by targeting endothelial cells. A number of
the targets of E7080 are also expressed on tumor cells and here we have looked at the direct effects of E7080 on
tumor cell behavior.
Methods: Using a panel of human tumor cell lines we determined the effect of E7080 on cell proliferation,
migration and invasion. Inhibition of FGFR and PDGFR signaling in the cells was measured.
Results: E7080 had little effect on tumor cell proliferation. However, it blocked migration and invasion at
concentrations that inhibited FGFR and PDGFR signaling. Knock-down of PDGFR-b in U2OS osteosarcoma cells also
inhibited cell migration which, could not be further inhibited in the presence of E7080. Furthermore, E7080 could
not inhibit the migration of a PDGFR negative cell line.
Conclusion: E7080 does not significantly affect tumor cell proliferation but can inhibit their migration and invasion
at concentrations that both inhibit its known targets and are achievable clinically.
Background
Angiogenesis, the formation of new blood vessels, is
required for tumor growth and metastasis [1,2]. The ability
of tumors to promote angiogenesis is driven by expression
of pro-angiogenic factors such as VEGF, bFGF, PDGF and
transforming growth factor-b (TGF-b) of which VEGF is
the most important [1,3]. VEGF exerts its actions through
two receptor tyrosine kinases, VEGFR-1 and VEGFR-2,
but it is signaling via VEGFR-2 that is important for
tumor angiogenesis [4]. A third VEGF receptor VEGFR-3,
is important for lymphangiogenesis and is activated by
two different ligands, VEGF-C and VEGF-D [5]. In view of
the dependence of tumors on angiogenesis for sustained
growth, targeting angiogenesis has been the focus of much
research into new anti-cancer therapies in recent years [6].
Direct angiogenesis inhibitors target endothelial cells by
inhibiting their ability to proliferate, migrate and form
new blood vessels. The first example of this was the use of
an antibody to VEGF, which was able to inhibit the growth
of tumors in mouse models [7]. Subsequently a humanized
version of this antibody, bevacizumab, was developed
which showed promising evidence of efficacy in pre-
clinical models. However, this was not translated into the
clinical setting. With the exception of renal carcinoma and
glioblastoma multiforme [8,9], bevacizumab appears to
have little activity as a single agent, although it does confer
significant benefit when combined with cytotoxic agents
and is now approved by the US Food and Drug Adminis-
tration for use in colorectal, breast, lung and renal cancer,
and glioblastoma multiforme. Other approaches to target
angiogenesis have centered on the use of small molecule
kinase inhibitors, which target VEGFR-2. Many of these
inhibitors are multi-targeted with additional activity
against one or a number of other receptor tyrosine
kinases. One such inhibitor is E7080, an orally active
multi-targeted tyrosine kinase inhibitor, which is currently
in clinical development. Three dose escalation phase I
trials of E7080 have now been performed, examining dif-
ferent dosing schedules [10-12]. In view of promising anti-
tumor effects observed, a number of disease specific phase
II and III trials, including melanoma, renal, thyroid, ovar-
ian, hepatocellular and endometrial cancer, are now
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underway. E7080 is a potent inhibitor of VEGFR-2 and
VEGFR-3 with IC50s of 4 and 5.2 nM respectively, but also
has activity against VEGFR-1, FGFR-1, and PDGFRa/b
tyrosine kinases although the IC50s are around 10 fold
higher [13]. E7080 shows anti-tumor activity in human
cancer cell xenografts, which has been attributed to its
ability to inhibit angiogenesis predominantly through
effects on VEGFR-2 inhibition but also through inhibition
of KIT and FGFR-1 [13-15]. Inhibition of VEGFR-3
mediated lymphangiogenesis by E7080 also contributed to
its ability to suppress lymph node and lung metastases in
a mammary tumor model [16]. Although these effects
were not mediated via direct effects of E7080 on tumor
cells two of the main targets of E7080, FGFR-1 and
PDFGR, are expressed in a number of solid tumors. We
therefore set out to determine whether E7080, in addition
to effects on angiogenesis, could directly affect the beha-
vior of epithelial tumor cells.
FGFR-1 amplification and over expression has been
reported in a sub-set of breast cancers [17], lung squa-
mous cell carcinoma [18] and also in oral squamous car-
cinoma, rhabodomyosarcoma, ovarian and bladder
cancer [19]. In melanoma there is evidence for a bFGF/
FGFR-1 autocrine loop driving proliferation in vivo
[20,21] indicating that in some tumor types inhibitors
such as E7080 may also have direct effects on the prolif-
eration of tumor cells. The PDGFR and its ligands are
also expressed in a number of different tumor types
including gliomas, breast and ovarian cancer and there is
evidence for PDGFR autocrine growth control in gliomas
[22,23]. However, PDGFR signaling is also important in
tumor stromal cells and many effects of PDGF in tumor
cells may be mediated via paracrine activation of stromal
cells [24,25] and in particular endothelial cells [23,26].
The effects of E7080 on tumor angiogenesis may there-
fore in part be mediated via inhibition of PDGFR signal-
ing in endothelial cells. A number of small molecule
tyrosine kinase inhibitors that target both the FGFR and
the PDGFR are now in clinical development, although,
like E7080, they also inhibit a number of other receptor
tyrosine kinases making it difficult to determine the
importance of targeting each individual receptor kinase
to tumor development [19,22,27].
Cancer cell proliferation is often regarded as the most
important aspect of cancer progression, and traditionally,
anti-cancer treatment has focused on preventing growth
of the tumor. However, other key aspects play a crucial
role in cancer progression, including tissue invasion and
metastasis [28]. A malignant tumor’s ability to invade
and migrate differentiates it from a benign tumor, and
hence these processes are crucial for cancer progression.
90% of human cancer deaths are caused by distant metas-
tases and therefore preventing cancer spread could have
a huge impact on patient survival. Signaling via both the
FGFR-1 and PDGFR has been associated with increased
migration, invasion and metastatic potential [29-33].
We therefore set out to determine whether E7080 has
any direct effects on tumor cell proliferation, migration
and invasion. We show that although there was very little
effect of E7080 on the proliferation of a range of human
tumor cell lines both their migration and invasion could
be blocked at concentrations of E7080 that inhibited sig-
naling through FGFR-1 and PDGFR-b. Furthermore, we
show that U2OS osteosarcoma cell migration was inhib-
ited by both E7080 and knock-down of PDGFR-b expres-
sion suggesting that E7080 may directly affect the
migratory capacity of tumor cells by targeting PDGFR-b.
The ability of E7080 to inhibit both migration and inva-
sion in vitro implies that it could potentially have signifi-
cant benefit in the prevention (or at least in the reduction)
of development of tumor metastases in vivo.
Methods
Cell culture and reagents
A375, U2OS, DU145 and human umbilical vein endothe-
lial cells (HUVECs) were obtained from the American
Type Culture Collection (Manassas, VA, USA). KM12C
cells were from I Fidler (MD Anderson Cancer Centre,
Houston, TX, USA) and DX3 and SK23 cells were a kind
gift from B Ozanne (Beatson Institute, Glasgow, UK).
DU145 and KM12C cells were grown in RPMI-1640
supplemented with 10% fetal bovine serum (FBS) and
2 mM glutamine and MEM supplemented with 10% FBS
and 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM
non-essential amino acids respectively. HUVECs were
grown in media 199 supplemented with 20% FBS, heparin,
1% penicillin/streptomycin/fungizone and endothelial cell
growth supplement. All other cell lines were grown in
DMEM supplemented with 10% FBS and 2 mM gluta-
mine. FBS was obtained from Autogen Bioclear (Calne,
UK) and all other tissue culture reagents from Invitrogen
(Paisley, UK). All lines were maintained in a humidified
atmosphere of 5% CO2 at 37°C and were serum starved
prior to growth factor stimulation. Growth factor treat-
ments were: bFGF (100 ng/ml, 15 min), PDGF-BB (50 ng/
ml, 15 min) and VEGF-A (100 ng/ml, 15 min)(all Upstate
Biotechnology, Waltham, MA, USA). E7080 (Eisai Co.
Ltd., Ibaraki, Japan) was prepared as a 10 mM stock in
DMSO and diluted in culture media prior to use. For
PDGFR-b knock-down experiments cells were transfected
with either 50 nM of ON-TARGETplus SMARTpool
PDGFR-b or non-targeting siRNA oligonucleotides
according to the manufacturers guidelines (Dharmacon,
Thermo Scientific, Loughborough, UK). 72 hours after
transfection cell extracts were prepared or cells were pla-
ted out for wound healing assays as described below.
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Cell proliferation assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) proliferation assays were carried out as
described previously [34]. Cells were treated with a
range of E7080 concentrations for 72 hours. Curve fit-
ting and generation of IC50 values was carried out using
GraphPad Prism 4 software from quadruplicate wells.
Immunoprecipitation and immunoblot analysis
Cell extracts were prepared as described previously [34]
and then immunoprecipitated with PDGFR-b (Upstate
Biotechnology), FRS2 (Santa Cruz, Santa Cruz, CA,
USA) or VEGFR-2 (Cell Signaling, Danvers, MA, USA)
antibodies overnight. Immune complexes were collected
with protein-A or protein-G sepharose beads (Sigma,
Gillingham, UK) and immunoblot analysis then carried
out as described previously [34] using the above antibo-
dies and also an anti-phosphotyrosine antibody (PY20,
BD Transduction Laboratories, Oxford, UK).
Migration assays
Cells were plated in 6 well plates at low cell density.
After 24 hours E7080 was added and images captured
every 5 minutes for 16 hours on a Nikon TE2000 micro-
scope using a 10× objective. Image J software was used
to track the cell nuclei of 20 separate cells per condition
over time and calculate the total accumulated distance,
euclidean distance (straight line distance travelled) and
velocity. Wound healing assays were carried out on con-
fluent monolayers of cells after ‘wounds’ were made by
scoring the monolayer with a fine pipette tip. E7080 was
then added and images captured every 15 minutes for
16 hours on a Nikon TE2000 microscope using a 10×
objective. Wound closure was then quantified using
Image J by calculating the distance between the wound
edges from 8 images per treatment condition.
Invasion assay
Inverse invasion assays were performed as described
previously using FBS as a chemoattractant [35]. In brief,
cells were seeded on the bottom of Transwell inserts
(Corning, Fisher Scientific, Loughborough, UK) contain-
ing polymerized collagen type I (Becton Dickinson,
Oxford, UK). Transwell inserts were then placed in
serum-free medium and medium supplemented with
10% FBS was placed on top of the matrix in the pre-
sence or absence of E7080. Five days after seeding
invading cells were stained with Calcein AM (Invitro-
gen) and visualized using a Leica SP2 confocal micro-
scope. Serial optical sections were captured at 15 μm
intervals and quantified using ImageJ analysis software.
Invasion was calculated as cells that had moved more
than 20 μm into the collagen.
Results
Effects of E7080 on tumor cell proliferation
Initially we chose a panel of 6 human cell lines repre-
senting a number of different tumor types and carried
out MTT assays to determine the effect of E7080 on
their proliferation. Dose-response curves for E7080 are
shown in Figure 1 from which the IC50 value for E7080
in each cell line was calculated (Table 1). In the majority
of the cell lines, E7080 only inhibited proliferation at
high concentrations (mean IC50s 23.6 - 44.17 μM) while
the IC50 in the KM12C colon cancer cell line was
9.54 μM.
Inhibition of FGFR-1 and PDGFR-b signaling by E7080
To establish the concentration of E7080 required to
inhibit activation and downstream signaling from
FGFR-1 and PDGFR-b we chose two cell lines which
expressed both receptors: DX3 melanoma and U2OS
osteosarcoma. PDGFR-b autophosphorylation in
response to stimulation with its ligand PDGF-BB was
used as a measure of PDGFR-b activation. PDGFR-b
phosphorylation was seen in both DX3 and U2OS cells
following stimulation with PDGF-BB (Figures 2A and
2B). Treatment with E7080 resulted in a dose-depen-
dent inhibition of PDGFR-b phosphorylation in both
cell lines with concentrations of 1 μM and above
resulting in complete inhibition (Figures 2A and 2B).
Direct measurement of FGFR-1 autophosphorylation
was not possible due to the lack of FGFR-1 antibodies
for western blotting and immunoprecipitation. The sig-
naling cascade downstream of FGFR-1 activation by its
ligand involves tyrosine phosphorylation of an adaptor
protein FRS2 followed by the recruitment of several
signaling molecules and subsequent activation of path-
ways such as the MAPK signaling pathway. FRS2 phos-
phorylation is FGFR-1 dependent and acts as a read
out of FGFR-1 activity in the cells. DX3 and U2OS
cells were treated with increasing concentrations of
E7080 and then stimulated with bFGF. A marked
increase in FRS2 phosphorylation was observed in DX3
cells following bFGF stimulation (Figure 2C). There
was a dose dependent inhibition of bFGF stimulated
FRS2 phosphorylation by E7080 with complete inhibi-
tion seen at concentrations of 1 μM and above (Figure
2C). There was also a dose dependent inhibition of
bFGF-induced phosphorylation of FRS2 in U2OS cells
with again concentrations of 1 μM resulting in com-
plete inhibition (Figure 2D). For comparison we also
looked at the ability of E7080 to inhibit VEGF-A
induced activation of VEGFR-2 in HUVECs. Treatment
with VEGF-A resulted in phosphorylation of VEGFR-2,
which was inhibited by pre-treatment with E7080 at
concentrations as low as 0.01 μM (Figure 2E).
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E7080 inhibits cell migration and invasion
Initially the effect of E7080 on the random migration of
DX3 and U2OS cells was measured using time lapse
videomicroscopy. E7080 treatment (both at 1 μM and
10 μM) resulted in a significant inhibition of both accu-
mulative (total) and euclidean (total straight line) dis-
tance moved and this was also reflected in a reduction
in the mean velocity of both cell lines (Figure 3A and
3B). To assess the effects of E7080 on directional cell
migration wound healing assays were performed. In the
presence of E7080 (both at 1 μM and 10 μM) the ability
of both cell lines to move into the wounded area was
significantly impaired. Importantly inhibition of cell
migration was seen with concentrations as low as 1 μM
E7080, which correlated with the concentration required
to inhibit FGFR-1 and PDGFR signaling in these cells
(Figure 2). Complete inhibition of cell migration was
not seen in either cell lines indicating that other path-
ways that are not targeted by E7080 are also involved in
their migration. E7080 also inhibited the ability of DX3
cells to invade into a Matrigel plug. Compared to
untreated cells, invasion was significantly reduced to
45% by 1 μM E7080 and to 13% by 10 μM E7080
(Figure 4A and 4B). The reduction in invasion after
treatment with E7080 was not due to an inability of
cells to migrate across the Transwell filter, as there was
no difference in the number of cells on the top of the
filter in the presence of E7080 (Figure 4C).
PDGFR-b signaling is required for U2OS cell migration
As there is a large body of evidence linking PDGF
receptor signaling with cell migration [36] we next set
out to determine whether targeting PDGFR-b signaling
could inhibit U2OS cell migration. PDGFR-b expression
was knocked down in U2OS cells by siRNA (Figure 5A).
Knock-down of PDGFR-b by siRNA resulted in a signifi-
cant inhibition of cell migration while treatment with
scrambled siRNA sequences had no effect (Figure 5B).
Treatment with 10 μM E7080 resulted in a similar
reduction in wound closure as PDGFR-b siRNA (35%
versus 38% reduction respectively, p = 0.57). Treatment
of U2OS cells with both E7080 and PDGFR-b siRNA
did not result in a further inhibition of cell migration as
compared to either treatment alone (Figure 5B), suggest-
ing that the ability of E7080 to inhibit migration is
mediated via inhibition of PDGFR-b signaling. To
further explore whether the effect of E7080 on cell
migration was mediated via inhibition of PDGFR-b,
wound healing assays were performed using the human
prostate cancer cell line DU145 that does not express
PDGFR-b protein [37,38]. In the presence of both 1 μM
and 10 μM E7080 no inhibition of DU145 migration
was observed (Figure 5C).
Discussion
E7080 is a promising new multi-targeted kinase inhibi-
tor that is currently in clinical development. The main
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Figure 1 Effect of E7080 on tumor cell proliferation. Dose-response curves for E7080 in a panel of cell lines. Results are shown from
representative experiments for each cell line in a series of at least 3 where values are the mean of 4 replicates.
Table 1 IC50 values for E7080 in a panel of cell lines
Cell line Origin IC50(μM)
a 95% Confidence interval
A375 Melanoma 44.17 37.24 - 51.09
DU145 Prostate cancer 23.62 20.02 - 27.20
DX3 Melanoma 33.95 21.11 - 46.79
KM12C Colon cancer 9.54 7.94 - 11.14
SK23 Melanoma 42.57 40.19 - 44.94
U2OS Osteosarcoma 34.82 31.36 - 38.28
aMean values from at least 3 experiments
Glen et al. BMC Cancer 2011, 11:309
http://www.biomedcentral.com/1471-2407/11/309
Page 4 of 10
D bFGF (100 ng/ml) - +      +     +      +      +
E7080 (M) - - 0.01  0.1    1     10 
pTyr
FRS2 
IP: FRS2
PDGF-BB 50 ng/ml - +      +      +     +     +
E7080 (M) - - 0.01  0.1    1    10                             
pTyr
PDGFR-ȕ
A
PDGF-BB 50 ng/ml - +     +     +      +     +
E7080 (M) - - 0.01  0.1    1    10
pTyr
PDGFR-ȕ
B
IP: PDGFR-ȕ
IP: PDGFR-ȕ
A
B
bFGF (100 ng/ml)     - +     +      +      +     +
E7080 (M)     - - 0.01  0.1    1    10 
pTyr
FRS2
IP: FRS2
C
VEGF 20 ng/ml  - +      +      +     +     +
E7080 (M) - - 0.01  0.1    1    10
pTyr
VEGFR-2
IP: VEGFR-2
E
Figure 2 Inhibition of PDGFR-b and FGFR-1 signaling by E7080. (A) DX3 and (B) U2OS cells were treated with increasing concentrations of
E7080, then stimulated with PDGF-BB. Lysates were prepared and the PDGFR-b immunoprecipitated and the immune complexes resolved by
SDS-PAGE and probed with an anti-phosphotyrosine (pTyr) antibody. Membranes were then stripped and reprobed with an anti-PDGFR-b
antibody. (C) DX3 and (D) U2OS cells were treated with increasing concentrations of E7080, then stimulated with bFGF. Lysates were prepared
and FRS2 immunoprecipitated and the immune complexes then resolved by SDS-PAGE and probed with an anti-pTyr antibody. Membranes
were then stripped and reprobed with an anti-FRS2 antibody. (E) HUVECs were treated with increasing concentrations of E7080, then stimulated
with VEGF-A. Lysates were prepared and the VEGFR-2 immunoprecipitated and the immune complexes then resolved by SDS-PAGE and probed
with an anti-pTyr antibody. Membranes were then stripped and reprobed with an anti-VEGFR-2 antibody.
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targets of E7080 are VEGFR-2 and VEGFR-3 and the
preclinical work to date has focused on the anti-angio-
genic activity of E7080. However, in this study we show
that E7080 also has direct effects on tumor cells at con-
centrations that correlate with inhibition of other
known targets, notably FGFR-1 and PDGFR-b. E7080
was able to inhibit both tumor cell migration and inva-
sion but had little effect on tumor cell proliferation. As
with many molecularly targeted agents there still remain
questions about the clinical utility of E7080 in terms of
which patients will benefit and in which setting treat-
ment with E7080 would be most appropriate. A detailed
preclinical investigation of the mechanism of action of
drugs such as E7080, which have multiple kinase targets,
is therefore essential to maximize its potential clinical
application. FGFR-1 and PDGFR-b are both widely
expressed in epithelial tumors and there is growing
interest in both of these kinases as potential targets
although many of the inhibitors currently available, as
with E7080, also inhibit a number of other kinases
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Figure 4 Inhibition of DX3 cell invasion by E7080. (A) Invasion of DX3 cells into Matrigel in the presence or absence of E7080 was measured:
DX3 cells were stained with calcien AM and images taken every 15 μm. (B) Quantification of invasion is shown for a representative experiment
in a series of three. Values are mean + s.e.m. of two transwells with 4 fields per transwell. p values comparing treated cells with controls were
calculated using Paired t-test. (C) The fluorescent intensity of DX3 cells on the upper side of the Transwell was measured in untreated and E7080
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[19,22,27]. It is likely therefore that such inhibitors will
have multiple effects on both tumor cells and associated
endothelial and stromal cells.
The pharmacokinetic analyses of patient samples from
the phase I clinical trial of E7080 indicated that patients
on the higher dose cohorts (receiving doses that will be
recommended for further clinical development) typically
achieved peak plasma concentrations of greater than 1 μM
(manuscript submitted). This would suggest that inhibi-
tion of FGFR and PDGFR-b should be occurring in
patients receiving treatment doses of E7080 and is greatly
in excess of the concentrations required to inhibit
VEGFR-2 activity (Figure 2). Inhibition of tumor cell pro-
liferation was only seen at very high concentrations of
E7080. These were in excess both of those achieved clini-
cally and those required to inhibit the main known targets
of E7080. This is in agreement with previous studies,
which have shown minimal effects of E7080 on tumor cell
growth in vitro [13]. However, the situation in vivo may be
very different as the tumor micro-environment often plays
an important part in tumor growth. For example, there is
evidence that melanoma is driven in part by bFGF acting
on FGFR-1 on tumor cells. bFGF is released from tumor
cells, endothelial cells and surrounding stromal cells, and
therefore acts in an autocrine and paracrine fashion. This
may lead to high local concentrations of bFGF, which may
then be important for driving tumor cell proliferation. In
addition over-expression of receptors or activating muta-
tions may mean that some tumor cells are more depen-
dent on these kinases for proliferation.
Although the evidence for direct effects of E7080 on
tumor proliferation are not compelling we did see signifi-
cant effects of E7080 on tumor cell migration and invasion
at concentrations that both inhibit its known targets and
are achievable clinically. Our data suggests that these
effects of E7080 may be due to inhibition of PDGFR sig-
naling. PDGFR signaling has been known for many years
to regulate cell migration [36,39] via activation of a
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Figure 5 PDGFR-b is required for U2OS cell migration. (A) Cell lysates were prepared following transfection of U2OS cells with PDGFR-b or
non-targeting siRNA oligonucleotides and PDGFR-b immunoprecipitated. The immune complexes were resolved by SDS-PAGE and probed with
an anti-PDGFR-b antibody. (B) Wound healing assays with U2OS cells were carried out in the presence or absence of E7080 and/or PDGFR-b
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number of signaling pathways including small Rho
GTPases, phosphatidylinositol (PI)3-kinase and phospholi-
pase (PL)C-g [36] and in tumor cells this has been linked
to activation of PI3-kinase [29,40]. PDGF signaling also
regulates the invasion of tumor cells [29,31,41]. In pan-
creatic cancer this is associated with PDGF induced phos-
phorylation of MUC1 a transmembrane glycoprotein
involved in pancreatic tumor progression and metastasis
[31]. PDGFR signaling has been implicated in the develop-
ment of metastases in a variety of human tumors, includ-
ing oesophageal cancer [42], colorectal cancer [24,25],
pancreatic cancer [31], sarcoma [43] and non-small cell
lung cancer [44]. In addition in a mouse model of mam-
mary carcinogenesis autocrine PDGFR signaling promotes
metastasis through regulation of an epithelial-to-mesench-
ymal transition (EMT) and treatment with the PDGFR
inhibitor imatinib suppressed metastasis [30].
In addition to our reported effects of E7080 on cell
migration and invasion, E7080 significantly reduced lym-
phatic vessel density in MDA-MB-231 mammary tumor
xenografts, which corresponded to a complete inhibition of
both lymph node metastasis and lung metastasis in E7080-
treated mice, thought to be due to the effects of E7080 on
VEGFR-3 activity [16]. Thus in addition to effects on angio-
genesis E7080 may have additional effects on the develop-
ment of metastases. Anti-invasive strategies are increasingly
being investigated in patients with cancer. However, the
clinical development of anti-invasive therapies is often
hampered by their lack of direct anti-tumour effects and
the difficulties involved with trial design and as yet it is not
clear how they will be used in the clinical setting.
Conclusions
E7080 does not significantly affect tumor cell prolifera-
tion but can inhibit their migration and invasion. Direct
effects of multi-kinase inhibitors such as E7080 on
tumor cells should be considered as they enter the clinic
and based on these findings, and given the knowledge
we have gained regarding the favorable efficacy and tol-
erability of E7080 (even after long term use), considera-
tion should be made to the potential effects of E7080 on
the development of metastatic disease.
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